ITRI-2531

N/A

Report date: 2025/02/01 20:00:06

NME

Base Information

Drug NameITRI-2531

Drug Alias NameITRI-2531

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionPlatelet-derived growth factor receptor beta inhibitorsVascular endothelial growth factor receptor 3 antagonistsTyrosine-protein kinase receptor FLT3 inhibitors +[5]

TargetsVascular endothelial growth factor receptor 3Platelet-derived growth factor receptor betaVascular endothelial growth factor receptor 2 +[5]

Therapy Area/IndicationsCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwan

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesIndustrial Technology Research Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesIndustrial Technology Research Institute

Active IndicationsN/A

Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A